I-Tech expects limited financial impact from EU non-renewal of Selektope approval
Bitget2026/11/03 13:11- I-Tech expects limited financial impact from EU member states' vote against renewing Selektope's approval; a final EU decision remains pending.
- Direct exposure to regional EU demand represents approximately 4% of total turnover.
- Approximately 95% of the global commercial fleet is expected to remain able to apply and operate with Selektope-containing coatings.
- EU supply and application are expected to continue for 180 days following adoption and publication of a formal non-renewal decision.
- The company intends to challenge aspects of the assessment through scientific, regulatory and legal channels; its long-term strategy remains unchanged.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
Itaúsa Q3 2026 recurring net profit rises 25% to R$ 5.06 billion year-on-year
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
Crypto prices
More
